Journal of Hepatology
Volume 51, Issue 4 , Pages 628-631 , October 2009

HCV reinfection studies and the door to vaccine development

  • Jason Grebely

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 376 Victoria Street, Sydney NSW 2010, Australia
  • ,
  • David L. Thomas

      Affiliations

    • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    • Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
  • ,
  • Gregory J. Dore

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 376 Victoria Street, Sydney NSW 2010, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 2 93850900; fax: +61 2 93850876.

  • Image Result

    Impact of sampling frequency on perceptions of reinfection outcome. Hypothetical virological profiles in (A) a participant with initial spontaneous HCV clearance, several HCV reinfection events with r

    Impact of sampling frequency on perceptions of reinfection outcome. Hypothetical virological profiles in (A) a participant with initial spontaneous HCV clearance, several HCV reinfection events with reduced duration and peak HCV viremia and subsequent spontaneous clearance of reinfection in each instance; (B) a participant with initial spontaneous HCV clearance, several HCV reinfection events with similar duration and peak HCV viremia and subsequent spontaneous clearance of reinfection in each instance; and (C) a participant with spontaneous HCV clearance and HCV reinfection with persistent viremia. Solid lines indicate HCV RNA levels (light grey shading indicates persistent viremia). HCV RNA assessment time points are indicated by vertical dotted lines. Legends indicate the hypothetical frequency of HCV RNA testing (in weeks), the number of viremic events that would be identified with such a hypothetical HCV RNA testing frequency and the apparent outcome of infection based on the last available time point for that HCV RNA testing frequency.

 The authors who have taken part in this study declared that they do not have anything to declare regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00460-7

doi: 10.1016/j.jhep.2009.07.002

Journal of Hepatology
Volume 51, Issue 4 , Pages 628-631 , October 2009